Medicilon was selected into the SSE Science and Technology Innovation Board 100 Index, R&D intensity and revenue growth have been recognized

On August 7, 2023, the Shanghai Stock Exchange officially launched the SSE Science and Technology Innovation Board 100 Index, a new index added to the STAR Market.  The SSE Science and Technology Innovation Board 100 Index selects 100 stocks with medium market capitalization and good liquidity from the STAR Market as index samples, and together with the SSE Science and Technology Innovation Board 50 Index to constitute the SSE Science and Technology Innovation Board Scale Index Series.  Shanghai Medicilon Inc. (Medicilon, stock code “688202.SH”) was selected as one of the SSE Science and Technology Innovation Board 100 Index.

The SSE Science and Technology Innovation Board 100 Index has distinct characteristics. Taking the latest sample as an example, the Chinese pharmaceutical industry accounts for nearly 30% of the SSE Science and Technology Innovation Board 100 Index.  In terms of innovation capability and performance growth, the total investment in research and development of the SSE Science and Technology Innovation Board 100 Index sample companies in 2022 is RMB 28.9 billion, accounting for an average of 19% of operating income.  The average compound annual growth rate of operating income of the sample companies in the past three years is as high as 38.9%, and the R&D intensity and revenue growth rate are both higher than the average level of the STAR market.    From 2019 to 2022, Medicilon’s revenue has tripled, and its net profit attributable to the parent company has increased by 5 times, and the overall development trend will continue to rise.